Intratumoral CD3+ T-lymphocytes immunoexpression and its association with c-Kit, angiogenesis, and overall survival in malignant canine mammary tumors

Analytical Cellular Pathology (Amsterdam)
Maria Isabel CarvalhoFelisbina L Queiroga

Abstract

In this study 80 malignant CMT were submitted to immunohistochemical detection of CD3, c-kit, VEGF, and CD31, together with clinicopathological parameters of tumor aggressiveness. CD3+ T-cells and c-kit overexpression revealed a positive correlation with VEGF (r = 0.503, P < 0.0001; r = 0.284, P = 0.023 for CD3 and c-kit, resp.) and CD31 (r = 0.654, P < 0.0001; r = 0.365, P = 0.003 for CD3 and c-kit, resp.). A significant association (P = 0.039) and a positive correlation (r = 0.263, P = 0.039) between CD3 and c-kit were also observed. High CD3/VEGF, c-kit/VEGF, and CD3/c-kit tumors were associated with elevated grade of malignancy (P < 0.0001 for all groups), presence of intravascular emboli (P < 0.0001 for CD3/VEGF and CD3/c-kit; P = 0.002 for c-kit/VEGF), and presence of lymph node metastasis (P < 0.0001 for all groups). Tumors with high CD3/VEGF (P = 0.006), c-kit/VEGF (P < 0.0001), and CD3/c-kit (P = 0.002) were associated with poor prognosis. Interestingly high c-kit/VEGF tumors retained their significance by multivariate analysis arising as independent prognostic factor.

References

Jan 8, 1999·The Journal of Veterinary Medical Science·K KuboY Takamori
Dec 13, 2003·Clinical & Experimental Metastasis·Chang Dae KoSei Hyun Ahn
Apr 22, 2004·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Maria MoriniLuciana Mandrioli
Apr 11, 2006·Molecular Cancer Research : MCR·Haitian LuChuanshu Huang
Jul 13, 2006·Clinics·Alexandre Henrique MacchettiSérgio Bighetti
Mar 10, 2007·Current Medicinal Chemistry·A E RoussidisN K Karamanos
Sep 4, 2007·The Breast : Official Journal of the European Society of Mastology·Alberto MantovaniPaola Allavena
Jul 29, 2008·The Breast : Official Journal of the European Society of Mastology·Bor-Ching SheuSong-Nan Chow
May 27, 2009·Carcinogenesis·Francesco ColottaAlberto Mantovani
Feb 12, 2010·Annals of the New York Academy of Sciences·Prabir RayAnuradha Ray
Apr 21, 2010·Cancer Metastasis Reviews·David G DeNardoLisa M Coussens
Jul 7, 2010·Cell·Mark A Lemmon, Joseph Schlessinger
Aug 3, 2010·The Veterinary Journal·Felisbina L QueirogaCarlos S Lopes
Jan 27, 2011·Veterinary Pathology·M GoldschmidtV Zappulli
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Sep 23, 2011·The Journal of Veterinary Medical Science·Kohei SaekiTakayuki Nakagawa
Mar 13, 2012·Melanoma Research·Joana GomesIsabel Pires
Mar 5, 2013·Indian Journal of Pathology & Microbiology·Maha M AminOmar Farouk
May 17, 2013·International Journal of Biological Sciences·Jing LiangHiroshi Sugiyama
Oct 5, 2013·Research in Veterinary Science·Maria Isabel CarvalhoFelisbina L Queiroga
Dec 5, 2013·Current Opinion in Allergy and Clinical Immunology·Timothy B OrissAnuradha Ray
Mar 29, 2014·BioMed Research International·Maria Isabel CarvalhoFelisbina L Queiroga
Jul 17, 2014·Journal of Comparative Pathology·B BrunettiG Sarli

❮ Previous
Next ❯

Citations

Apr 1, 2020·International Journal of Molecular Sciences·Joanna K BujakKinga Majchrzak-Kuligowska
Jan 11, 2020·Frontiers in Cell and Developmental Biology·Enni Markkanen
Jan 6, 2017·BioMed Research International·Maria Isabel CarvalhoFelisbina L Queiroga
Mar 9, 2021·Frontiers in Veterinary Science·Guillermo ValdiviaLaura Peña
Jul 6, 2019·Journal of Veterinary Research·Marta SzwedaAndrzej Pomianowski

❮ Previous
Next ❯

Software Mentioned

SPSS ( Statistical Package for the Social Sciences )

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.